Active Biotech AB (publ) (0GQU.L)

1.0135 +1.0135 (+88.99%) At close: 01:15PM BST

Active Biotech AB (publ)

Scheelevägen 22
Lund 223 63
Sweden
46 46 19 20 00
https://www.activebiotech.com

Sector(s): 
Industry: 
Full-time employees: 8

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Helen Tuvesson Ph.D.	President & CEO	4.04M	N/A	1962
Mr. Hans Kolam	Chief Financial Officer	N/A	N/A	1951
Dr. Erik Vahtola	Chief Medical Officer	N/A	N/A	1976

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.

Corporate governance

Active Biotech AB (publ)’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.